[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"carcinoma-ovarian-epithelial\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:carcinoma-ovarian-epithelial":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,78,106,135],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100644487","blood-based-minimal-residual-disease-in-advanced-epithelial-ovarian-cancer-after-1st-line-therapy-100644487",false,"NCT07670962","Blood-Based Minimal Residual Disease in Advanced Epithelial Ovarian Cancer After 1st Line Therapy","The Role of Blood-Based Minimal Residual Disease in Patients With Advanced Epithelial Ovarian Cancer After 1st Line Therapy","Inclusion Criteria:\n\nWomen aged 19 years or older. Pathologically confirmed high-grade serous, endometrioid, clear cell, or mixed type ovarian cancer.\n\nFIGO stage III or IV. Patients who have completed primary debulking surgery (PDS) or interval debulking surgery (IDS) and platinum-based chemotherapy (subsequent maintenance therapy, such as bevacizumab or PARP inhibitors, is allowed).\n\nPatients showing radiological or clinical Complete Response (CR) after the completion of platinum-based chemotherapy.\n\nWritten informed consent for the study.\n\nExclusion Criteria:\n\nRadiological progressive disease during or immediately after treatment. Expected survival of 3 months or less. Immunodeficiency or pathological bleeding tendencies. Unable to undergo blood tests or unwilling to undergo repeated blood sampling. Concurrent other solid tumors or history of malignant tumors within the last 5 years.\n\nRefusal to consent to participate in this study.","FEMALE","19 Years",{"count":19,"type":20},300,"ESTIMATED","3 Years","OBSERVATIONAL","The purpose of this observational study is to learn if a specialized blood test can help predict whether advanced ovarian cancer will return after a patient's initial treatments are finished.\n\nResearchers are inviting women who have been diagnosed with stage III or IV epithelial ovarian cancer and have recently completed their first-line treatments, which include surgery and platinum-based chemotherapy.\n\nThe study focuses on \"circulating tumor DNA\" (ctDNA), which are tiny fragments of genetic material that cancer cells release into the bloodstream as they break down. Finding these DNA fragments in the blood when a patient appears to be cancer-free on standard tests is known as assessing for minimal residual disease (MRD).\n\nBecause this is an observational study, participants will receive standard medical care as directed by their doctor. For the research portion, participants will provide blood samples at specific times: at the time of diagnosis, shortly after surgery, right after finishing their first-line chemotherapy, and then every 3 months during regular follow-up visits. Researchers will also analyze a sample of the tumor tissue that was already removed during the patient's standard surgery.\n\nBy tracking these participants for up to 3 years, researchers hope to discover if the ctDNA test can accurately identify patients who have a high risk of their cancer returning, and if it can detect this earlier than traditional imaging scans or standard blood tests like CA-125.",[25,26,27],"Ovarian Neoplasms","Carcinoma, Ovarian Epithelial","Ovarian Cancer",[29,30,31,32],"ctDNA","Minimal Residual Disease","MRD","Liquid Biopsy","NOT_YET_RECRUITING","2026-06-22",{"date":36,"type":37},"2026-06-26","ACTUAL",{"date":39,"type":20},"2026-07-01",{"date":41,"type":20},"2028-12-31",{"name":43,"class":44},"Asan Medical Center","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":52,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100377571","phase-1-bp1001-a-in-patients-with-advanced-or-recurrent-solid-tumors-100377571","NCT04196257","BP1001-A in Patients With Advanced or Recurrent Solid Tumors","A Phase I\u002FIb Study of BP1001-A (a Liposomal Grb2 Antisense Oligonucleotide) in Patients With Advanced or Recurrent Solid Tumors","Inclusion Criteria:\n\n1. All participants, ≥ 18 years of age, with histologic evidence of advanced or recurrent solid tumors, who are not candidates for regimens or protocol treatments known to confer clinical benefit.\n2. ECOG Performance Status Score of 0 or 1.\n3. Participants must be willing to undergo pre-treatment biopsies. Participants who complete 1 cycle of treatment will undergo post-treatment biopsies. Post-treatment biopsies will be offered to participants who do not complete 1 cycle of treatment.\n4. For the dose expansion phase, participants must have recurrent or persistent epithelial ovarian, primary peritoneal, fallopian tube or endometrial tumor and must be participants for whom single agent paclitaxel would be considered a reasonable treatment option.\n5. Endometrial cancer patients with the following histologic epithelial cell types are eligible: Endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified, mucinous adenocarcinoma, squamous cell, transitional cell carcinoma, and mesonephric carcinoma.\n\n   Ovarian tumor patients with the following histologic epithelial cell types are eligible: High-grade serous carcinoma, endometrioid carcinoma, clear cell carcinoma, squamous carcinoma, transitional cell (Brenner) carcinoma, mixed epithelial-stromal carcinoma, undifferentiated or other epithelial carcinoma.\n\n   Uterine carcinosarcoma and other sarcomas of the uterus are not eligible.\n6. Estimated life expectancy \\> 3 months in the Investigator's opinion.\n7. All participants must have measurable disease per RECIST criteria v1.1. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded). Each lesion must be \\>\u002F= 20 mm when measured by conventional techniques, including plain x-ray, CT, and MRI, or \\>\u002F= 10 mm when measured by spiral CT. Measurable disease lesions must be amenable to pre- and post-treatment biopsy.\n8. Participants must have at least one \"target lesion\" to be used to assess response on this protocol as defined by RECIST v1.1. Tumors within a previously irradiated field will be designated as \"non-target\" lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy.\n9. Participants must have adequate:\n\n   1. Bone marrow function: HgB \\>\u002F= 9 g\u002FdL, WBC \\>\u002F= 3,000\u002FmcL, ANC \\>\u002F= 1,500\u002FmcL, PLT \\>\u002F= 100,000\u002FmcL\n   2. Hepatic function: Total bilirubin within normal institutional limits, AST and ALT \\\u003C 2.5 X institutional ULN\n   3. Renal function: Serum creatinine \\\u003C 1.5 x ULN or eGFR \\> 60 mL\u002Fmin according to Cockcroft-Gault formula\n   4. Neurologic function: Neuropathy (sensory and motor) \\\u003C\u002F= CTCAE Grade 1\n   5. Blood coagulation parameters: PT such that INR is \\\u003C 1.5 (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin or low molecular weight heparin) and a PTT \\\u003C 1.2 times control\n10. Participants previously treated with docetaxel (regardless of response) are eligible for this trial.\n11. Participants in the dose expansion phase who previously received paclitaxel for primary or recurrent disease are eligible if they did not progress on therapy or relapse within 6 months of completing therapy. Participants with persistent disease at the completion of primary therapy with paclitaxel are not eligible.\n12. Participants should be free of active infection requiring antibiotics, with the exception of uncomplicated UTI.\n13. Any hormonal therapy directed at the malignant tumor must be discontinued at least two weeks prior to BP1001-A treatment. Continuation of hormone replacement therapy is permitted; stable regimens of hormonal therapy for prostate cancer (e.g., leuprolide, a gonadotropin-releasing hormone \\[GnRH\\] agonist), ovarian or breast cancer are not exclusionary.\n14. Any other prior therapy directed at the malignant tumor, including immunologic agents, must be discontinued at least four weeks prior to first dose of BP1001-A (6 weeks for nitrosoureas or mitomycin C).\n15. Female participants of childbearing potential must have a negative urine pregnancy test performed within 24 hours prior to the start of study treatment. Post-menopausal subjects (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test.\n16. Female participants of childbearing potential must agree to use an acceptable method of birth control (i.e., a hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide or abstinence) for the duration of the study and for at least 6 months after the last dose of treatment.\n17. Male participants must agree to use an acceptable method of contraception for the duration of the study.\n18. Participants must be willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n1. For the dose expansion phase, participants must not have low grade serous ovarian carcinoma or mucinous ovarian carcinoma.\n2. For the dose expansion phase, participants must wait at least two weeks after receiving any strong inhibitor, inducer, or substrate of both CYP3A4 and CYP2C8 before investigational drug administration.\n3. Participants who had previous bone marrow or hematopoietic stem cell transplant.\n4. Participants may not be receiving any other investigational agents.\n5. Female participants who are pregnant or breast-feeding.\n6. History or evidence upon physical examination of CNS disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack or subarachnoid hemorrhage within 6 months of registration on this study.\n7. Within the past 6 months, participant has had any of the following: myocardial infarction, unstable angina pectoris, coronary\u002Fperipheral artery bypass graft, cerebrovascular accident, or transient ischemic attack.\n8. Presence of concurrent conditions that, in the opinion of the Investigator and\u002For Medical Monitor, may compromise the participant's ability to tolerate study treatment or interfere with any aspect of study conduct or interpretation of results. This includes, but is not limited to, unstable or uncontrolled angina, NYHA class III or IV congestive heart failure, uncontrolled and sustained hypertension, clinically significant cardiac dysrhythmia, or clinically significant baseline ECG abnormality (e.g., QTcF \\>470 msec).\n9. Active pleural effusion or pleural or pericardial effusion with symptoms. Pleural or pericardial effusion that has received treatment and resolved according to the Investigator, is acceptable.\n10. Participants who are ineligible to undergo an MRI scan for reasons such as claustrophobia or the presence of implanted devices or metallic foreign bodies that are not MR compatible, such as ferromagnetic implants or pacers or with a known history of allergic reaction to gadolinium contrast agents.\n11. Any condition which, in the Investigator's opinion, makes the subject unsuitable for trial participation.\n12. A prior history of ≥ Grade 3 hypersensitivity to paclitaxel or docetaxel or with products mixed in Cremephor EL or Tween 80®.\n13. Unresolved toxicity higher than CTCAE Grade 1 attributed to any prior therapy or procedure, excluding alopecia.\n14. Substance abuse, medical, psychological, or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.\n15. Participants with HIV infection who have CD4+ T-cell counts \\\u003C 350 cells\u002FmcL or with clinically active hepatitis B or C infection.\n16. Participants who have a major surgical procedure, open biopsy, dental extractions, or other dental surgery\u002Fprocedure that results in an open wound, or significant traumatic injury within 28 days prior to the first date of treatment on this study, or anticipation of need for major surgical procedure during the course of the study; patients with placement of vascular access device or core biopsy within 7 days prior to registration.\n17. (For dose expansion phase) Subjects ineligible or unable to receive paclitaxel as treatment for their disease.","ALL","18 Years",{"count":55,"type":20},50,"INTERVENTIONAL",[58],"PHASE1","This is a phase I, open-label, study of BP1001-A in participants with advanced or recurrent solid tumors. The dose escalation phase will determine the safety and the maximum tolerated dose (MTD) or maximum administered dose (MAD) of BP1001-A as a single agent. After the MTD or MAD of BP1001-A is established, the dose expansion phase will commence and determine the safety, toxicity and response of BP1001-A in combination with paclitaxel.",[61,26,62,63,64,65],"Solid Tumor, Adult","Fallopian Tube Neoplasms","Endometrial Cancer","Peritoneal Cancer","Solid Tumor","RECRUITING","2025-03-06",{"date":69,"type":37},"2025-03-07",{"date":71,"type":37},"2022-08-19",{"date":73,"type":20},"2027-10",{"name":75,"class":76},"Bio-Path Holdings, Inc.","INDUSTRY",4,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":52,"minAge":53,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":56,"phases":87,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100360735","development-of-a-cinical-and-biological-database-in-ovarian-fallopian-tube-and-peritoneal-cancers-100360735","NCT03976999","Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers","Development of a Prospective and Monocentric Cinical and Biological Database in Epithelial Ovarian Cancer, Fallopian Tube Cancer and Primitive Peritoneal Cancer","BCBOvaire","Inclusion Criteria:\n\n* 18 or older\n* Patient at the diagnosis of an epithelial ovarian cancer, or a fallopian tube caner or a primitive peritoneal cancer\n* Patient eligible for, at least, one surgery and a chemotherapy\n* Patient having given his informed, written and express consent\n\nExclusion Criteria:\n\n* Patient not affiliated to a social protection scheme\n* Pregnant and \u002F or nursing women\n* Subject under tutelage, curatorship or safeguard of justice\n* Patient whose regular follow-up is impossible for psychological, familial, social or geographical reasons",{"count":19,"type":20},[88],"NA","A Clinical and Biological Database will provide to the scientific community a collection of blood and tissues with clinical datas to improve knowledge about cancer and help to develope new cancer treatments. This database is specific to epithetial ovarian cancer, Fallopian tube cancer and Primitive peritoneal cancer.",[26,62,91],"Peritoneal Neoplasms",[93,94,95],"Biological Specimen Banks","Cancer","Gynecology","2025-02-11",{"date":98,"type":37},"2025-02-12",{"date":100,"type":37},"2017-07-05",{"date":102,"type":20},"2032-07",{"name":104,"class":44},"Institut du Cancer de Montpellier - Val d'Aurelle",1,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":56,"phases":116,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":134},"100485486","phase-3-letrozole-for-estrogenprogesterone-receptor-positive-low-grade-serous-epithelial-ovarian-cancer-lepre-trial-100485486","NCT05601700","Letrozole for Estrogen\u002FProgesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)","Letrozole for Estrogen\u002FProgesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer: a Randomized Phase III Trial (LEPRE Trial)","LEPRE","Inclusion Criteria:\n\nI - 1. Age ≥ 18 years. I - 2. Newly diagnosed, low-grade serous carcinoma of the ovary including cancer of fallopian tube and peritoneum (invasive micropapillary serous carcinoma or invasive grade 1 serous carcinoma). This is to be confirmed via nuclear p53 immunohistochemistry testing by a central pathology review performed at the Coordinating Centre.\n\nI - 3. Immunohistochemically determined positivity (≥ 10%) for ER and\u002For PgR expression. This is to be confirmed by centralized review.\n\nI - 4. Patients must have undergone an upfront surgery with maximal cytoreductive effort, with either optimal or suboptimal residual disease status.\n\nI - 5. Stage III-IV according to 2018 FIGO classification. For proper staging:\n\n* Patients must have undergone contrast-enhanced CT-scan of the chest, abdomen and pelvis within 28 days prior to randomization. If CT-scan is not recommended (e.g. for allergy to contrast agent) MRI or 18F-FDG PET\u002FCT-scan are allowed.\n* The imaging evaluation must be accompanied by an anamnestic and physical examination within 14 days prior to randomization.\n\nI - 6. Postmenopausal, defined as any of the following criteria:\n\n* Patients who underwent bilateral salpingo-oophorectomy;\n* Monolateral salpingo-oophorectomy, amenorrhea for 12 or more consecutive months and age ≥60 years;\n* Monolateral salpingo-oophorectomy, amenorrhea for 12 or more consecutive months, age \\\u003C60 years and FSH and serum estradiol levels within the laboratory's reference ranges for post-menopausal women.\n\nI - 7. Randomization must take place within 60 days of primary cytoreductive surgery.\n\nI - 8. Eastern Cooperative Oncology Group - performance status (ECOG-PS) 0-1.\n\nI - 9. To be able to take oral medications.\n\nI - 10. Adequate bone marrow, hepatic and renal functions as defined below:\n\n* Absolute neutrophil count (ANC) ≥ 1500\u002Fmm3\n* Platelets ≥ 100,000\u002Fmm3\n* Hemoglobin ≥ 10.0 g\u002FdL\n* Total bilirubin ≤ 1.5 x Upper Limit of Normal (ULN)\n* ALT and AST ≤ 3.0 x ULN\n* Alkaline phosphatase ≤ 2.5 x ULN\n* Albumin ≥ 2.8 g\u002FdL\n* Serum creatinine ≤ 1.5 x ULN.\n\nI - 11. Written informed consent obtained prior to any study-specific procedure.\n\nExclusion Criteria:\n\nE - 1. Other malignancy within the last 5 years, except for non-melanoma skin cancer adequately treated.\n\nE - 2. Neoadjuvant chemotherapy or radiotherapy for the treatment of this disease.\n\nE - 3. Previous hormonal therapy for the treatment of this disease.\n\nE - 4. Known hypersensitivity to letrozole or known hypersensitivity\u002Fintolerance to carboplatin\u002Fpaclitaxel therapy.\n\nE - 5. Active or uncontrolled systemic infection.\n\nE - 6. Known central nervous system metastases.\n\nE - 7. Severe cardiac disease, such as myocardial infarction or unstable angina within 6 months prior to randomization.\n\nE - 8. New York Heart Association (NYHA) Class III or greater congestive heart failure.\n\nE - 9. Neuropathy grade 2 or higher.\n\nE - 10. History of fractures of the spine or femur not properly treated.\n\nE - 11. Known osteoporosis (dual-energy x-ray absorptiometry (DEXA) of the femoral neck T score of -2.5 or lower) not adequately treated with bisphosphonates or RANKL inhibitors.\n\nE - 12. Concomitant use of inducers of CYP3A4 (e.g. phenytoin, rifampicin, carbamazepine, phenobarbital, and St. John's Wort) which may reduce exposure to letrozole. Concomitant use of medicinal products with a narrow therapeutic index that are substrates for CYP2C19 (e.g. phenytoin, clopidrogel) that may have their systemic serum concentrations altered by letrozole.\n\nE - 13. Concurrent severe medical problems or any condition that would significantly limit full compliance with the study.",{"count":115,"type":20},132,[117],"PHASE3","This is an Italian, multicenter, randomized, open-label phase III trial which will evaluate if Letrozole is superior to standard adjuvant chemotherapy in patients with hormone receptor positive low-grade serous epithelial carcinoma of the ovary (LGSCO).\n\nThe hypothesis is that letrozole will significantly prolong median progression free survival (PFS) compared with the standard chemotherapy treatment, namely carboplatin AUC 5 and paclitaxel 175 mg\u002Fm2.",[26,120],"Low Grade Serous Adenocarcinoma of Ovary",[122,123,124],"Estrogen\u002Fprogesteron receptor positive tumor","Letrozole","Aromatase Inhibitors","2025-01-23",{"date":127,"type":37},"2025-01-27",{"date":129,"type":37},"2022-09-22",{"date":131,"type":20},"2029-09-22",{"name":133,"class":44},"Ente Ospedaliero Ospedali Galliera",19,{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":56,"phases":144,"briefSummary":146,"conditions":147,"keywords":154,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":105},"100402352","phase-2-pembrolizumab-and-lenvatinib-for-platinum--sensitive-recurrent-ovarian-cancer-100402352","NCT04519151","Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer","A Phase II, Open Lable, Single Arm, Trial to Determine Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab for Platinum- Sensitive Recurrent Ovarian Cancer","Inclusion Criteria:\n\n1. Female participants who are at least 18 years of age on the day of signing informed consent, with histologically-confirmed diagnosis of EOC (except from low grade tumors and mucinous histology).\n2. A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:\n\n   1. Not a woman of childbearing potential (WOCBP) OR\n   2. A WOCBP who agrees to follow the contraceptive during the treatment period and for at least 120 days after the last dose of study treatment.\n3. The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.\n4. Have measurable disease at baseline based on RECIST 1.1. Lesions\n5. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n6. Have received a front-line platinum-based regimen per local standard of care or treatment guideline following the primary or interval debunking surgery with radiologically documented disease recurrence no earlier than 6 months following completion of platinum-based therapy.\n\nNote: Maintenance treatment following front-line treatment is permitted and counted together as part of the front-line treatment. Recurrence is evaluated since last platinum-based chemotherapy administration (for patients treated with maintenance bevacizumab or PARP inhibitors) Note: Patients that received maintenance immune checkpoint inhibitors will be eligible if progression was documented over 6 months since completion of the immunotherapy maintenance treatment.\n\nHave received 0 to 1 line of chemotherapy for ROC (or 1 to 2 total prior lines counting the front line) and must have a PFI (or treatment-free interval) of \\>6 months for each treatment line.\n\n8\\. Have provided archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated.\n\n9\\. Have adequately controlled blood pressure (BP) with or without antihypertensive medications 10. Have adequate organ function as defined by blood tests.\n\nExclusion Criteria:\n\n1. A WOCBP who has a positive urine pregnancy test\n2. The participant is pregnant or breastfeeding at Screening or Baseline, or is expecting to conceive within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment.\n3. The participant has received prior therapy with an anti-PD-1, anti-PD-L1 oranti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX-40, CD137) in the last 6 months (6 months are calculated from the last dose until study initiation).\n4. The participant has received prior systemic anti-cancer therapy mAb, chemotherapy or targeted small molecule therapy within 4 weeks prior to the planned first dose of the study, including investigational agents within 4 weeks. For tyrosine kinase inhibitors (TKIs), other than lenvatinib, and hormonal therapy a shorter interval of 5 half-lives is allowed between prior therapy and study treatment initiation.\n\n   Note: Participants must have recovered from all AEs due to previous therapies to ≤Grade 1 or baseline. Participants with ≤Grade 2 neuropathy may be eligible.\n5. The participant has received prior lenvatinib.\n6. The participant has received prior radiotherapy within 2 weeks of start of study treatment.\n7. The patient had prior grade 3 immune related toxicity due to immune checkpoint inhibitors or non-infectious pneumonitis.\n8. The participant has received more than 2 prior chemotherapy lines.\n9. The participant has a history of tumor bleeding one month before study enrollment.\n10. The participant has received a live vaccine within 30 days prior to the first dose of study drug.\n11. The participant is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.\n\n    Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent.\n12. The participant has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.\n\n    Note: The use of physiologic doses of corticosteroids is allowed.\n13. The participant has a known active second\u002Fadditional malignancy that is progressing or has required active treatment within the past 5 years Note: Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, in situ cervical cancer.\n14. The participant has a known active CNS metastases and\u002For carcinomatous meningitis.\n\n    Note: Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.\n15. The participant has severe hypersensitivity (≥Grade 3) to pembrolizumab and\u002For any of excipients.\n16. The participant has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs).\n\n    Note: Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.\n17. The participant has an active infection requiring systemic therapy.\n18. The participant has a known history of human immunodeficiency virus (HIV 1\u002F2 antibodies).\n19. The participant has a known history of hepatitis B or known active hepatitis C virus\n20. The participant has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n21. The participant has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n22. The participant has had an active allogenic tissue\u002Fsolid organ transplant.\n23. The participant has uncontrolled blood pressure\n24. The participant has clinically significant electrolyte abnormalities that have not been corrected.\n25. The participant has significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction or cerebrovascular accident (CVA) within 6 months of the first dose of study drug, or cardiac arrhythmia associated with hemodynamic instability requiring medical treatment at Screening.\n26. The participant has bleeding or thrombotic disorders, radiographic evidence of major blood vessel invasion\u002Finfiltration, or is at risk for severe hemorrhage.\n\n    Note: The degree of tumor invasion\u002Finfiltration of major blood vessels (e.g. carotid artery) should be considered because of the potential risk of severe hemorrhage associated with tumor shrinkage\u002Fnecrosis following lenvatinib therapy.\n27. The participant has \\>1+ proteinuria on urine dipstick testing unless a 24-hour urine collection for quantitative assessment indicates that the urine protein is \\\u003C1 g\u002F24 hours.\n28. Prolongation of QTc interval to \\>480 ms.\n29. Left ventricular ejection fraction (LVEF) below the institutional normal range as determined by multigated acquisition scan (MUGA) or echocardiogram (ECHO).\n30. The participant has gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib.\n31. The participant has a pre-existing Grade ≥3 gastrointestinal or non-gastrointestinal fistula.\n32. The participant has a known intolerance to the study treatment (or any of its excipients).",{"count":143,"type":20},24,[145],"PHASE2","This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) for the treatment of platinum sensitive recurrent ovarian cancer. Participants will receive pembrolizumab and lenvatinib.",[25,26,148,149,150,151,152,153],"Neoplasm of Stomach","Ovarian Diseases","Genital Neoplasms, Female","Ovarian Epithelial Tumor","Urogenital Neoplasms","Neoplasms, Glandular and Epithelial",[27,155,156,157,158],"Platinum sensitive","Ovarian Epithelial","Neoplasms","Genital Neoplasms","2023-06-06",{"date":161,"type":37},"2023-06-08",{"date":163,"type":37},"2021-04-12",{"date":165,"type":20},"2029-11",{"name":167,"class":168},"Sheba Medical Center","OTHER_GOV"]